NASDAQ:CSII - Cardiovascular Systems Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$35.61 +1.42 (+4.15 %)
(As of 02/20/2019 04:00 PM ET)
Previous Close$34.19
Today's Range$34.20 - $35.70
52-Week Range$20.89 - $40.00
Volume288,893 shs
Average Volume290,465 shs
Market Capitalization$1.24 billion
P/E Ratio712.20
Dividend YieldN/A
Cardiovascular Systems, Inc., a medical device company, develops, manufactures, and commercializes various devices to treat vascular and coronary diseases in the United States. The company offers peripheral arterial disease products, including Diamondback 360 Peripheral, Predator 360, Stealth 360 Peripheral Orbital Atherectomy System (OAS), Diamondback 360 60cm Peripheral OAS, Diamondback 360 Low Profile Peripheral, Diamondback 360 1.50 Peripheral, Diamondback 360 2.00 Peripheral, Diamondback 360 200cm Peripheral, and Diamondback 360 180cm Peripheral, which are catheter-based platforms for treating a range of plaque types in leg arteries above and below the knee, including calcified plaque, as well as address various limitations associated with surgical, catheter, and pharmacological treatment alternatives. It also provides Diamondback 360 Coronary OAS, an atherectomy device for the treatment of calcified coronary arteries. Cardiovascular Systems, Inc. was founded in 1989 and is headquartered in St. Paul, Minnesota.

Receive CSII News and Ratings via Email

Sign-up to receive the latest news and ratings for CSII and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
Current SymbolNASDAQ:CSII



Sales & Book Value

Annual Sales$217.04 million
Cash Flow$0.1798 per share
Book Value$3.98 per share


Net Income$1.71 million


Market Cap$1.24 billion

Cardiovascular Systems (NASDAQ:CSII) Frequently Asked Questions

What is Cardiovascular Systems' stock symbol?

Cardiovascular Systems trades on the NASDAQ under the ticker symbol "CSII."

How were Cardiovascular Systems' earnings last quarter?

Cardiovascular Systems Inc (NASDAQ:CSII) issued its earnings results on Wednesday, January, 30th. The medical device company reported $0.01 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.04) by $0.05. The medical device company had revenue of $60.21 million for the quarter, compared to analysts' expectations of $59.66 million. Cardiovascular Systems had a return on equity of 1.28% and a net margin of 0.74%. View Cardiovascular Systems' Earnings History.

When is Cardiovascular Systems' next earnings date?

Cardiovascular Systems is scheduled to release their next quarterly earnings announcement on Wednesday, May 1st 2019. View Earnings Estimates for Cardiovascular Systems.

What guidance has Cardiovascular Systems issued on next quarter's earnings?

Cardiovascular Systems updated its FY 2019 earnings guidance on Wednesday, January, 30th. The company provided EPS guidance of for the period. The company issued revenue guidance of $243-247 million, compared to the consensus revenue estimate of $244.95 million.

What price target have analysts set for CSII?

4 analysts have issued 12 month price objectives for Cardiovascular Systems' stock. Their predictions range from $45.00 to $50.00. On average, they expect Cardiovascular Systems' stock price to reach $47.50 in the next twelve months. This suggests a possible upside of 33.4% from the stock's current price. View Analyst Price Targets for Cardiovascular Systems.

What is the consensus analysts' recommendation for Cardiovascular Systems?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cardiovascular Systems in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cardiovascular Systems.

What are Wall Street analysts saying about Cardiovascular Systems stock?

Here are some recent quotes from research analysts about Cardiovascular Systems stock:
  • 1. According to Zacks Investment Research, "Cardiovascular Systems exited first-quarter fiscal 2019 on a mixed note. The company continued to see increased revenues from Atherectomy franchises, growing international sales of OAS and top-line contributions from its emerging product pipeline. We are also upbeat about Cardiovascular Systems’ recent announcement of the first global commercial use of Stealth 360 Peripheral OAS in Hong Kong. Further, the company is progressing well with the international distribution agreement with OrbusNeich to sell its coronary and peripheral OAS outside the United States and Japan. According to management, the company saw the strongest quarterly growth in the first quarter in the last 18 months. Over the past six months, Cardiovascular Systems has outperformed its industry. On the flip side, the company faces cut-throat competition in the niche space. Further, its failure to enter global markets might affect results." (11/12/2018)
  • 2. Needham & Company LLC analysts commented, "CSII’s F1Q19 revenue beat while EPS missed consensus and management maintained FY19 revenue guidance. While CSII should continue to benefit from the Japanese launch, an exclusive international distribution agreement (OrbusNeich), new support products, and building rep productivity, we believe there is execution risk in CSII’s long-term transformation (see our analyst meeting note here). Given these points, increasingly difficult comps in FY19, and our belief that CSII shares are fairly valued, we maintain our Hold rating." (10/31/2018)

Has Cardiovascular Systems been receiving favorable news coverage?

News articles about CSII stock have been trending neutral recently, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Cardiovascular Systems earned a daily sentiment score of 0.3 on InfoTrie's scale. They also gave news articles about the medical device company a news buzz of 5.0 out of 10, indicating that recent media coverage is somewhat likely to have an effect on the company's share price in the next several days.

Who are some of Cardiovascular Systems' key competitors?

Who are Cardiovascular Systems' key executives?

Cardiovascular Systems' management team includes the folowing people:
  • Mr. Scott Raymond Ward M.S., MS, B.Sc., Chairman, Pres & CEO (Age 59)
  • Mr. Jeffrey S. Points, Chief Financial Officer (Age 42)
  • Ms. Rhonda J. Robb, Chief Operating Officer (Age 51)
  • Mr. Alexander Rosenstein, Gen. Counsel & Corp. Sec. (Age 47)
  • Ms. Laura J. Gillund, Chief Talent Officer (Age 58)

Who are Cardiovascular Systems' major shareholders?

Cardiovascular Systems' stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (8.33%), Partner Fund Management L.P. (4.59%), D. E. Shaw & Co. Inc. (2.40%), Frontier Capital Management Co. LLC (2.05%), New York State Common Retirement Fund (1.51%) and Northern Trust Corp (1.31%). Company insiders that own Cardiovascular Systems stock include Alexander Rosenstein, Edward M Brown, Jeffrey S Points, Kevin J Kenny, Laura Gillund, Laurence L Betterley, Martha Goldberg Aronson, Sandra Sedo and Scott R Ward. View Institutional Ownership Trends for Cardiovascular Systems.

Which major investors are selling Cardiovascular Systems stock?

CSII stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Two Sigma Investments LP, Acadian Asset Management LLC, Frontier Capital Management Co. LLC, Meeder Asset Management Inc., Bank of America Corp DE, GW&K Investment Management LLC and Barclays PLC. Company insiders that have sold Cardiovascular Systems company stock in the last year include Alexander Rosenstein, Jeffrey S Points and Sandra Sedo. View Insider Buying and Selling for Cardiovascular Systems.

Which major investors are buying Cardiovascular Systems stock?

CSII stock was acquired by a variety of institutional investors in the last quarter, including Partner Fund Management L.P., BlackRock Inc., Sectoral Asset Management Inc, Dimensional Fund Advisors LP, First Trust Advisors LP, Hsbc Holdings PLC, State Board of Administration of Florida Retirement System and Royce & Associates LP. Company insiders that have bought Cardiovascular Systems stock in the last two years include Martha Goldberg Aronson and Scott R Ward. View Insider Buying and Selling for Cardiovascular Systems.

How do I buy shares of Cardiovascular Systems?

Shares of CSII can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cardiovascular Systems' stock price today?

One share of CSII stock can currently be purchased for approximately $35.61.

How big of a company is Cardiovascular Systems?

Cardiovascular Systems has a market capitalization of $1.24 billion and generates $217.04 million in revenue each year. The medical device company earns $1.71 million in net income (profit) each year or $0.05 on an earnings per share basis. Cardiovascular Systems employs 652 workers across the globe.

What is Cardiovascular Systems' official website?

The official website for Cardiovascular Systems is

How can I contact Cardiovascular Systems?

Cardiovascular Systems' mailing address is 1225 OLD HWY 8 NW, ST. PAUL MN, 55112. The medical device company can be reached via phone at 651-259-1600 or via email at [email protected]

MarketBeat Community Rating for Cardiovascular Systems (NASDAQ CSII)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  340 (Vote Outperform)
Underperform Votes:  264 (Vote Underperform)
Total Votes:  604
MarketBeat's community ratings are surveys of what our community members think about Cardiovascular Systems and other stocks. Vote "Outperform" if you believe CSII will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CSII will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/20/2019 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel